coronary artery disease and acute coronary syndrome
Conditions
Interventions
Trade Name: PLAVIX 75 mg - Filmtabletten
Product Name: PLAVIX 75 mg - Filmtabletten
Pharmaceutical Form: Tablet
INN or Proposed INN: Clopidogrel
CAS Number: 113665-84-2
Concentration unit: mg milligra
Sponsors
Medizinische Universität Wien, Univ.Klinik f.Innere Medizin I, Abt.f.Hämatologie u.Hämostaseologie
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: -age between 19 and 50 years -normal findings on the medical history -body mass index (BMI) between 15th and 85th percentile of normal -non-smoking behaviour Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: -history of bleeding -allergy to or contraindication against ASA -history of or symptoms suggestive for gastrointestinal disease -abuse of alcoholic beverages -use of any medication within two weeks before blood sampling.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: - to compare the effects of clopidogrel and prasugrel on in vivo and ex vivo hemostatic system activation - to investigate the additional effect of ASA to clopidogrel or prasugrel with regard to their effects on in vivo and ex vivo hemostatic system activation ;Secondary Objective: -;Primary end point(s): – ß-TG in shed blood plasma – TxB2 in shed blood plasma – F1+2 in shed blood plasma – D-Dimer in shed blood plasma – number and cellular origin of TF exposing microparticles (MPs) in shed blood plasma | — |
Countries
Austria
Outcome results
None listed